NICE Doubtful On Cost-Effectiveness Of Tarceva

By Faraz Kermani / Email the Author / “The Pink Sheet” DAILY Feb. 17, 2012
Word Count: 554 / Article # 14120217002

Executive Summary

The U.K.’s National Institute for Health and Clinical Excellence is asking for a further cost-effectiveness analysis of Roche’s Tarceva to weigh against the cost effectiveness of AstraZeneca’s Iressa.

Purchase this Article

$35.00 Buy Now

For $35.00, purchase this 554-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

+ Show All | – Hide All

Offers & Events

Topics Covered in this Article

Click a keyword for related articles.
General Topics
NICE
Subjects
Comparative Effectiveness
Reimbursement
Cost Effectiveness
Government Payors
Ex-United States
Industries
Biopharmaceuticals
Branded Prescription
Therapeutic Area(s) of Focus
Cancer
Lung Cancer
Regions
Europe
United Kingdom
Companies
Roche
AstraZeneca PLC

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: NICE Doubtful On Cost-Effectiveness Of Tarceva

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Pink Sheet” DAILY will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel